quantisnow
FeedTopReportsPricing
⌘K
Live feed
09:15:00·143d
PRRelease
Creative Medical Technology Holdings Inc. logo

Creative Medical Technology Holdings Announces World Health Organization Approval of "olastrocel" as INN for Lead Allogeneic Cell Therapy CELZ-201

CELZ· Creative Medical Technology Holdings Inc.
Finance
Original source

Companies

  • CELZ
    Creative Medical Technology Holdings Inc.
    Finance

Recent analyst ratings

  • Feb 25UpdateRoth Capital$10.00

Related

  • SEC34d
    SEC Form 10-K filed by Creative Medical Technology Holdings Inc.
  • PR73d
    Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline
  • PR101d
    Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain
  • PR108d
    Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative
  • SEC113d
    Creative Medical Technology Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
  • SEC125d
    Creative Medical Technology Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
  • PR128d
    Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point
  • SEC128d
    SEC Form 424B3 filed by Creative Medical Technology Holdings Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022